论文部分内容阅读
目的:观察肝动脉化疗栓塞联合血管内皮抑制素介入治疗原发性肝细胞癌的疗效及其安全性。方法:50例原发性肝细胞癌患者接受肝动脉化疗栓塞联合血管内皮抑制素介入治疗。观察治疗后不良反应和近期疗效,以评价治疗的安全性和有效性。结果:50例原发性肝细胞癌患者接受肝动脉化疗栓塞联合血管内皮抑制素介入治疗后,主要不良反应包括Ⅰ～Ⅱ度骨髓抑制以及谷丙转氨酶和谷草转氨酶的升高,未发生严重的治疗相关不良反应。近期疗效显示,50例患者中部分缓解3例,疾病稳定40例,疾病进展7例,疾病控制率为86.0%。结论:肝动脉化疗栓塞联合血管内皮抑制素介入治疗原发性肝细胞癌是安全而有效的。
Objective: To observe the efficacy and safety of transcatheter arterial chemoembolization combined with endostatin in the treatment of primary hepatocellular carcinoma. Methods: Fifty patients with primary hepatocellular carcinoma underwent transcatheter arterial chemoembolization combined with endostatin interventional therapy. Adverse reactions and short-term efficacy after treatment were observed to evaluate the safety and efficacy of the treatment. Results: The main adverse reactions included Ⅰ ~ Ⅱ myelosuppression and elevated alanine aminotransferase and aspartate aminotransferase in 50 patients with primary hepatocellular carcinoma after interventional chemotherapy with hepatic arterial chemoembolization and endostatin. There was no serious Treatment-related adverse events. Recent results show that 50 patients partially relieved in 3 cases, 40 cases of stable disease, disease progression in 7 cases, the disease control rate was 86.0%. Conclusions: Hepatic arterial chemoembolization combined with endostatin intervention is safe and effective in the treatment of primary hepatocellular carcinoma.